smithklin lt skb aim pct earn rais smithklin beckman corp pursu point stragey achiev pct annual increas oper earn remaind decad smithklin earn mln dlr dlr share revenu billion dlr compani annual report nonpharmaceut busi play major role meet earn growth target fact grow faster pharmaceut busi smithklin major product antiulc medic tagamet report intend improv earn exist product expand product portfolio optim financi resourc bolster posit antiulc market tagamet met stiff competit smithklin strategi develop counter version tagamet bolster joint ventur lt wellcom plc pend ventur japan smithklin allergan eye skin care product divis billion dlr organ year grow pct annual nondilut acquisit real possibl gavin herbert presid eye skin care product group report allergan worldwid sale mln dlr smith kline french laboratori pharmaceut unit sale billion dlr file food drug administr market approv number cardiovascular agent includ tissu plasminogen activ year sk sale forc pct larger sale personnel smith kline small clinic laboratori test unit sale mln dlr perform mln test year see increas employe drug test test aid antibodi smith kline depend share price cost money buy back share year bought back pct share smithklin begin year manag team includ chief oper offic georg ebright